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Objective/background: Thalassemia is a monogenic hematologic disease that has the highest
prevalence globally. In addition, there is complexity of the genetic background associated with
a variety of phenotypes presented among patients. Genetic heterogeneity related to fetal
hemoglobin (HbF) production has been reported as an influencing phenotypic factor of
b-thalassemia (b-thal). Therefore, this study aimed to find the effect of these genetic modi-
fiers, especially in the XmnI locus, rs11886868, rs766432 (BCL11A), and rs9399137 (HBS1L-
MYB), among b-thal and HbE/b-thal patients in Indonesia, according to laboratory and clinicala Gumbreg
56 L. Rujito et al.outcomes, including HbF levels and clinical scores. This study was also designed to compare
these modifying effects among b-thal and HbE/b-thal patients in Indonesia.
Methods: A total of 189 patients with genotyping of b-thal and HbE/b-thal were included in this
study. The erythrocytes index and Hb electrophoresis measurements were calculated using
appropriate methods. The severity of b-thal and HbE/b-thal was classified based on the Mahidol
score. Polymorphism of the XmnI locus, rs11886868, rs766432 (BCL11A), and rs9399137 (HBS1L-
MYB) was determined using polymerase chain reaction–restriction fragment length polymor-
phism (PCR–RFLP) and amplification refractory mutation system (ARMS) methods.
Results: The distributions of minor allele in the XmnI locus, rs11886868, rs766432, and
rs9399137 were 14%, 22%, 19% and 18% respectively. The variation allele in the XmnI locus,
rs11886868, and rs766432 showed a significant value for modifying HbF and clinical score in
HbE/b-thal patients, but rs9399137 did not demonstrate such features. In b-thal patients, how-
ever, no correlation was found for any single-nucleotide polymorphisms and clinical appear-
ance.
Conclusion: The XmnI locus, rs11886868, and rs766432 have a modifying effect on HbF and
clinical score in HbE/b-thal patients in Indonesia, but not in b-thal patients.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
The inherited disorders of hemoglobin (Hb), a disease with
the highest prevalence and incidence rate worldwide, are
now becoming a serious health problem given the hundreds
of thousands of children who are born every year with these
disorders [1]. Eighty to ninety million people, or 1.5% of
the global population, are now carrying beta-thalassemia
alleles in their genetic make-up. Up to 60,000 children show
clinical symptoms and require hospital care [2]. For patients
with thalassemia, attention should not only be directed
toward the severity of the clinical appearance, but also
toward the complexity of the genetic background associ-
ated with the disease. So far, >800 types of mutations and
structural variants in the beta gene have been well charac-
terized using the existing genomic protocols [3]. Beta-
thalassemia (b-thal) itself has over 200 point mutations that
lead to various clinical states because of the varying
arrangements of compound heterozygous alleles. Clinical
features of this condition reflect on a wide range of transfu-
sion requirements from ‘‘do not require transfusions” to
‘‘regular transfusions” dependent [4].
HbE/b-thal, a compound heterozygous mutation of the
beta globin gene, is identified in 30–50% of patients with
thalassemia who require regular blood transfusions. In some
regions, for example, the northern part of Thailand and
Cambodia, this number has gone up to 70% [5]. Cryptic
mutations associated with codon 26 (GAG > AAG) result in
varying levels of HbE production. The clinical variability of
HbE/b-thal patients also correlates with the type of muta-
tion present in b-globin genes. However, variations in the
b-globin gene mutations in many instances are not enough
to explain the genotype–phenotype correlation in these
patients [6]. The phenotypic diversity of these conditions
are related to the influencing genetic factors, such as the
presence of mild/silent b-thal alleles, and co-inheritance
with a-thalassemia (a-b-thalassemia). Milder clinical
symptoms are allegedly caused by a better balance ratio
between the a-chain and the non-a-chain [7]. In particular,increasing fetal hemoglobin (HbF) level in many studies was
shown to affect the clinical outcome of patients with sickle
cell disease (SCD), b-thal, or HbE/b-thal [8,9].
Some genome-wide association studies have reported
that there are at least three major loci that play a major
role in increasing HbF levels. These include 158 C > T in
the promoter gene Gamma 2 (locus XmnI), intergenic
regions HBS1L-MYB in the 6q23.3 chromosomal region, and
the BCL11A gene on chromosome 2p16.1 [10–12]. The three
loci simultaneously have an influence on up to 20–50% of
HbF variation in patients with b-thal or in healthy adults
[6,13]. The effect of these loci has been studied among
European, African, American, and other Asian populations.
However, according to published literature, only a few
reports related to these loci in the Indonesia population
are available. Therefore, this study aimed to find the effect
of these genetic modifiers, especially in the XmnI locus—
rs11886868, rs766432 (BCL11A), and rs9399137 (HBS1L-
MYB)—among b-thal and HbE/b-thal patients in Indonesia,
according to laboratory and clinical outcomes, including
HbF levels and clinical scores.
Materials and methods
Patients studied were part of a preliminary study on genetic
epidemiology associated with b-thal in Central Java,
Indonesia [14]. A total of 189 patients with genotyping of
b-thal and HbE/b-thal were included in this study. An
informed consent form was presented to the patients or
their guardians and their consent was obtained. The ethical
clearance certificate and consent form regarding this
research was approved by the Medical Ethics Committee,
Faculty of Medicine, Jenderal Soedirman University, Central
Java, Indonesia. Patient registration was done in Banyumas
General Hospital (Purwokerto), in collaboration with the
Thalassemia Foundation of Indonesia. The severity of
b-thal and HbE/b-thal was classified based on the Mahidol
score. The clinical features considered included the first
time thalassemic symptoms appeared, the first time
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pretransfusion, periodicity of transfusion, and enlargement
of the spleen. The details on Mahidol score can be obtained
elsewhere [15]. The phenotypic score ranged between 0 (for
asymptomatic value) and 10 (for the worst appearance). For
calculating the erythrocytes index and for performing the
Hb electrophoresis test, we used XT 2000 (Sysmex, Lin-
colnshire, IL, USA), BioRad VARIANT Hemoglobin Analyzer
(Hercules, CA, USA), and Sebia CAPILLARYS 2 Flex (E´vry,
Essonne, France). Pretransfusion Hb sample was collected
from patients for 3 years. Polymorphism of the XmnI locus,
rs11886868, rs766432 (BCL11A), and rs9399137 (HBS1L-MYB)
was determined using polymerase chain reaction–restric-
tion fragment length polymorphism (PCR–RFLP) and ampli-
fication refractory mutation system (ARMS) methods.
Details of primers and enzymes used in this experiment
are presented in Table 1. DNA electrophoresis was carried
out on a 2.5% acrylamide gel. The DNA illumination band
was presented as follows: in the ARMS examination of
rs766432, a T allele was depicted as having 135 bp, whereas
a C allele was depicted as having 116 bp. In the ARMS exam-
ination of rs9399137, a T allele was depicted as having 243
bp, and the C allele was depicted as having 178 bp. In the
RFLP examination of rs11886868 with the MboII enzyme,
the T and C alleles were indicated as having 540 bp and
478 bp, respectively. The XmnI locus alleles were identified
as having 214 bp and 137 bp for the (+) allele, whereas the
51-bp, undigested PCR product was identified as the ()
allele.
A Hardy–Weinberg equilibrium (HWE) distribution was
established on each allele and the genetic associations of
single-nucleotide polymorphisms (SNPs) and clinical appear-
ance of HbF were analyzed through a linear regression
model using SNPStats, which is available online from Barce-
lona University, Barcelona, Spain [16]. An independent t
test was used to determine whether there were any differ-
ences between the HbF level distribution according to the
presence or absence of minor allele frequency in the studied
loci. A p value <.05 was considered statistically significant.
Ethical approval and informed consent
All procedures performed in this study were performed in
accordance with the ethical standards of the InstitutionalTable 1 Primers and enzymes used for polymerase chain reaction
refractory mutation system application.
Locus Primers
XmnI FG5: 50-GAGCTACAGACAAGAAGGTG-30
RG4: 50-TTTTATTCTTCATCCCTAGC-30
rs11886868 F868: 50-TTTGGTGCTACCCTGAAAGAC-30
R868: 50-ACTCAACAGTAGCAGAATGAAAGAG-30
rs766432 432(A)F: 50-TTGTTTCGCTTTAGCTTTATTAAGGTACA
432(A)R: 50-GACGTGTTCTGTATCTTGATTTTGGT-30
432(C)F: 50-CCAAACAGTTTAAAGGTTACAGACAGACT
432(C)R: 50-AAAATGAATGACTTTTGTTGTATGTAGAG
rs9399137 137(C)F: 50-AATGTAATTAACTGAACATATGGTTAGTC
137(C)R: 50-TTTATTGTTACAAGGTTAATTCACTGCC-
137(T)F: 50-GAAATACCATCACTGAGAAAAGCATAAG-
137(T)R: 50-CAGCAGGGTTGCTTGTGAAAAAACTT TAand/or National Research Committee and with the 1964 Hel-
sinki declaration and its later amendments or comparable
ethical standards. Certificate of Approval was obtained from
the Ethical Committee of Faculty of Medicine, Jenderal Soe-
dirman University, and Department of Education and Train-
ing, Banyumas Hospital, Central Java, Indonesia.
Informed consent was obtained from all individual partic-
ipants included in this study. The informed consent form
was approved by the Ethical Committee of the Faculty of
Medicine, Jenderal Soedirman University.
Results
Hematological index
Hematological values based on the type of allele found are
presented in Tables 2 and 3. The data obtained (Tables 2
and 3) indicate that the lowest pretransfusion Hb level pre-
sented in the b0/b0 alleles with the average of 7.4 g/dL [s-
tandard deviation (SD) 0.92]. The mean corpuscular
volume (MCV) and mean corpuscular hemoglobin (MCH) val-
ues were also low in the b0/b0 alleles. The hemoglobin A2
(HbA2) levels in b-thal mutations were in the range of
3.22% and 5.24%, whereas in the HbA/b-thal population,
the determination of HbA2 appeared to increase with the
average level of 40% (SD 11.49). This result was confirmed
by the presence of HbE, which has the same retention time
in the high-performance liquid chromatography machine.
The percentage of HbF in either b-thal or HbE/b-thal
patients increased from the normal value. The b-thal
patients showed HbF levels that varied from 59.7% to 91%,
especially in the b0/b0 genotypes with the highest value of
HbF was 81%; by contrast, HbE/b-thal patients had an aver-
age HbF level of 29%. It was also found that HbE/b-thal
patients have a better correlation with the HbF level and
the degree of the clinical score appearance than b-thal
patients (r = .49, p = .01), as depicted in Figure 1.
DNA transillumination
A typical band of DNA electrophoresis is shown in Figure 2.
Amplicons from a primer designed for the PCR method were
then digested with the appropriate enzymes. Positive–restriction fragment length polymorphism and amplification
Amplicons (bp) Enzyme Alleles interpretation
351 XmnI (+): 214, 137
(): 351
540 MboII C: 478, 62
T: 540
A-30 135 – A: 135
-30
-30
116 C: 116
-30
30
178 – C: 178
30
-30
234 T: 234
Table 2 Erythrocyte index and fetal hemoglobin level in various alleles of b-thalassemia patients.
Parameter b0/b0 (=7) b0/b+ (severe)
(n = 30)
b+ (severe)/b+
(severe)
(n = 31)
b+/b+
(severe)
(n = 4)
HbE/b+
(severe)
(n = 86)
HbE/b0
(n = 30)
p (F test)
Hb
pretransfusion
(g/dL)
7.40 ± 0.92 8.28 ± 0.53 8.36 ± 0.56 8.39 ± 0.42 8.28 ± 0.61 8.34 ± 0.49 .035
Mean
corpuscular
volume (fL)
73.23 ± 3.98 74.41 ± 4.45 78.51 ± 2.61 77.08 ± 3.96 79.05 ± 5.44 76.86 ± 4.00 .373
Mean
corpuscular
hemoglobin
(pg)
24.22 ± 1.65 25.94 ± 1.56 24.59 ± 2.10 25.56 ± 1.30 26.32 ± 0.96 24.60 ± 2.20 .326
Hemoglobin A2
(+HbE) (%)a
3.85 ± 1.01 3.85 ± 2.48 5.24 ± 2.91 3.22 ± 2.32 40.33 ± 11.49 40.77 ± 10.68 .005
Fetal
hemoglobin (%)
91.81 ± 2.10 69.08 ± 30.68 78.27 ± 24.49 59.70 ± 27 29.00 ± 11.41 29.45 ± 11.04 .002
a Hemoglobin A2 and Hemoglobin E (HbE) is on the same value (high-performance liquid chromatography Variant II).
Table 3 Alleles and genotypes percentage of XmnI, rs9399137, rs11886868, and rs766432.
Gene (chromosome) Single-nucleotide
polymorphism locus
Genotype Allele Hardy–Weinberg
equilibrium (v2)aType Frequency Proportion Type Frequency Proportion
HBG2 (11.p15.5) XmnI +/+ 7 0.04 + 53 0.14 0.063
/+ 39 0.21  325 0.86
/ 143 0.76
HBS1L-MYB (6.q23.3) rs9399137 C/C 10 0.05 C 69 0.18 0.085
T/C 49 0.26 T 309 0.82
T/T 130 0.69
BCL11A (2.p16.2) rs11886868 T/T 12 0.06 T 82 0.22 0.20
C/T 58 0.31 C 296 0.78
C/C 119 0.63
BCL11A (2.p16.2) rs766432 C/C 11 0.06 C 72 0.19 0.058
A/C 50 0.26 A 306 0.81
A/A 128 0.68
a v2 > 0.05 = alleles in the equilibrium.
58 L. Rujito et al.digestion indicated the presence of polymorphisms at these
sites. On the ARMS examination, a primer mismatch created
for the PCR amplification process showed the base sequence
polymorphism in accordance with the specific primer. A pos-
itive band corresponding to the specific primer showed the
type of polymorphism in question.
SNPs distribution and phenotypic relationship
Genotype distribution, allele proportions, and HWE are
determined using SNPStats software and depicted in Table 3.
Positive alleles (+) of XmnI constituted 14% of the whole
chromosomes examined, with a homozygosity (+/+) per-
centage of 4%. The major allele of the rs11886868 locus
was C, accounting for 78% of the total chromosomes. By
contrast, rs766432 and rs9399137 only had 19% and 18% ofminor allele C. Population alleles of each locus showed
HWE over 0.05.
Minor alleles at the polymorphism loci did not show a sig-
nificant relationship to changes in the HbF concentration
and the degree of clinical appearance of b-thal patients
(Table 4). Nevertheless, the mean levels of HbF and the
clinical scores of minor alleles showed a better value than
the wild-type allele. In the HbE/b-thal group, the minor
allele plays a role in increasing HbF concentrations mainly
in the XmnI locus, rs11886868, and rs766432 (Table 4),
whereas rs9399137 did not modify either the HbF level or
phenotype appearance.
Regression analysis carried out to understand the impact
of SNPs in shaping HbF levels in the HbE/b-thal patients
showed that rs766432 polymorphism displayed a better
coefficient (4.7%) in increasing the HbF level compared with
Figure 1 Relationship between fetal hemoglobin (HbF) level and clinical score in patients with b-thalassemia (b-thal) and
hemoglobin E/b-thal (HbE/b-thal). HbE/b-thal patients provide a better correlation with HbF and clinical score association (Pearson
r = .49 and p = .001), compared with b-thal patients (Pearson r = .01 and p = .98).
Figure 2 Transillumination DNA examination of XmnI, rs766432, rs11886868, and rs9399137. (A). Amplification refractory
mutation system (ARMS) examination of rs766432: Bands 1 and 4 are homozygous AA, Band 2 is homozygous CC, and Band 3 is
heterozygous AC. (B). ARMS examination of rs9399137: Band 1 is homozygous TT, Band 2 is homozygous CC, and Band 3 is
heterozygous TC. (C). Restriction fragment length polymorphism (RFLP) examination of rs11886868 with the MboII enzyme. Band 1 is
heterozygous TC, Band 2 is homozygous TT, and Band 3 is homozygous CC. (D). RFLP examination of XmnI locus with the XmnI
enzyme digestion. Band 3 shows the undigested polymerase chain reaction product reflecting the homozygous / genotype. Band 2
is homozygous +/+ and Band 1 is heterozygous /+.
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Table 4 Relationship between minor allele, fetal hemoglobin, and clinical presentation of b-thalassemia and hemoglobin E/b-
thalassemia.
Gene (chromosome) Locus Genotype Frequency Mean t test (p)
HbF (%) Clinical score Fetal hemoglobin Clinical score
b-thal patients
HBG2 XmnI / 55 75.12 6.33 0.67 0.24
(11.p15.5) /+ + +/+ 17 77.94 6.00
HBS1L-MYB rs9399137 TT 53 75.94 5.39 0.78 0.10
(6.q23.3) TC + CC 19 77.75 6.33
BCL11A rs11886868 CC 43 78.15 6.23 0.71 0.15
(2.p16.2) CT + TT 29 75.98 5.86
BCL11A rs766432 AA 55 75.56 5.47 0.70 0.17
(2.p16.2) AC + CC 17 77.81 6.27
HbE/b-thal patients
HBG2 XmnI / 88 31.32 6.15 0.01 0.02
(11.p15.5) /+ + +/+ 29 38.42 5.58
HBS1L-MYB rs9399137 TT 82 32.22 6.23 0.17 0.44
(6.q23.3) TC + CC 35 35.10 5.50
BCL11A rs11886868 CC 82 38.75 5.80 0.02 0.04
(2.p16.2) CT + TT 35 30.66 6.31
BCL11A rs766432 AA 73 31.80 6.20 0.01 0.02
(2.p16.2) AC + CC 44 35.21 5.69
60 L. Rujito et al.other polymorphisms. The determinant coefficient of the
XmnI allele was 3.2%, whereas that of rs11886868 was
2.8%. Meanwhile, the C allele at rs9399137 showed no signif-
icant association (p > .05; Table 5).
Discussion
Hematological features
In patients with thalassemia, especially those with tha-
lassemia intermedia and major, experts argue that the clin-
ical situation is not always directly proportional to the
specific type of mutation. Various factors affect the
patient’s clinical presentation. However, the International
Thalassaemia Federation agreed that the clinical distur-
bance is greatly influenced by the degree of red blood cell
indexes, primarily the Hb status [17]. The Hb status in this
study, however, showed significant improvement during
the study period, in both b-thal and HbE/b-thal patients.
In the beginning, before commencing routine transfusion,
the mean Hb levels were in the range of 4–6 g/dL (prelim-
inary data, unpublished). In the later stages, however, this
value increased up to 8 g/dL. This significant improvement
is attributed to our multiple efforts to improve patient’s
quality of life, one of which is to maintain Hb levels aboveTable 5 Regression value of XmnI, rs9399137, rs11886868, and r
Gene (chromosome) Locus Allele Allele frequenc
HBG2 (11.p15.5) XmnI + 0.14
HBS1L-MYB (6.q23.3) rs9399137 C 0.18
BCL11A (2.p16.2) rs11886868 C 0.88
BCL11A (2.p16.2) rs766432 C 0.199 g/dL with regular transfusions. This process significantly
reduces hepatosplenomegaly due to extramedullary hema-
topoiesis, bone deformity, and enlargement of the heart
[18].
Individuals with homozygous b-thal have similar Hb pre-
transfusion, MCV, and MCH values between the classification
of the type of mutation (73 fL and 74 fL for a mutation con-
taining the b0 allele, and 77 fL and 78 fL for the b+ mutation;
Table 2). In general, patients have lower Hb and red blood
cell indices than normal individuals. The Hb level in HbE/
b0-thalassemia patients showed slightly lower levels than
the b+ patients (severe). An extensive review conducted
by the Gene Reviews team noted that regardless of the
mutation, Hb, MCV, and MCH values in patients with tha-
lassemia major are at very low levels. They noted that Hb
level, in general, is <7 g/dL, MCV is between 50 fL and 70
fL, and MCH level is between 12 pg and 20 pg [18]. In line
with these findings, a previous Indonesian study noted that
Hb levels in patients with thalassemia in Semarang varied
from 4.3 f/dL to 12.5 g/dL with a mean value of 7.8 g/dL
[19], whereas in Jakarta and Bandung these values were
4.4–8.6 g/dL [20] and 7.3 g/dL [21], respectively.
In a previous study, the average Hb value of HbE/b-thal
patients without the co-inheritance involving the deletion
of a gene was 7.1 g/dL with an MCV below 60 fL [5]. Similars766432 for the fetal hemoglobin level.
y Correlation (r) Determinant coefficient (r2) (p)
.18 .032 .028
.06 .004 .395
.17 .028 .042
.19 .047 .039
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trated that the Hb level in HbE/b-thal patients with no
splenectomy or splenectomy is not much different, with
an average value between 7.6 g/dL and 7.9 g/dL [22]. Data
on Hb, MCV, and MCH in this study are slightly higher than
the existing data presented in previous publications. This
can be explained as follows: all patients in Banyumas,
regardless of the type of mutation, have been receiving a
regular blood transfusion to achieve Hb levels of over
10 g/dL. In addition, the patients were asked to return to
the hospital within 3–4 weeks for multiple rounds of trans-
fusion until this goal is achieved. It is to be noted that
patients with mutations in b+ may still have better pretrans-
fusion Hb level than those with b+ mutations.
Patients with the b0/b0 alleles showed the highest level
of HbF (91.81% ± 2.10%), whereas those with b+/b+ alleles
had HbF levels of 59.70% ± 27% [23]. These data indicate
that that b-thal patients have a wide range of HbF concen-
tration, which ranges from 50% to 98% under various circum-
stances (i.e., based on the type of mutation). Another study
reported that homozygous or compound heterozygous muta-
tions in b-thal patients produce HbF in the range of 70–90%
[18]. Our study patients presented HbF levels in the range of
80–98% (b0/b0), whereas the other allele group (b+/b+)
showed a highly variable level ranging from 50% to 98%. This
high value represents the inability of the cell to produce the
b-globin chain.
In the HbE/b-thal group, the HbF degree increased in
both b+ (29.00% ± 11.41%) and b0 alleles (29.45% ± 11.04%).
The increased level of HbF in HbE/b-thal patients is a
response to, or a compensation for, the reduced levels of
HbA and HbE to varying degrees due to cryptic mutations.
There are at least two basic mechanisms that play a role
in this regard: maintaining a high number of gamma-globin
chain and increasing the rate of erythropoiesis [24]. In a
subsequent study, large numbers of gamma globin chain
were noted due to suppression or variations in BCL11A
protein-coding genes and other transcription factors,
including EKLF and GATA1 [25]. With regard to the other
mechanism, overexpression of erythropoiesis increases the
concentration of erythrocyte F cells in peripheral blood cir-
culation [26].
In our study, the range of HbA2 in b-thal patients was
3.22–5.23%. According to a systematic review, this level
was in the normal range (2–5%) [18]. The HbE/b-thal
patients, however, had HbA2 levels of 40%. This high con-
centration is actually the resultant value of HbE and HbA2,
both of which have the same electrophoresis zone in the
high-performance liquid chromatography method [27,28].
These increased levels (i.e., 40%) are in accordance with
previous studies that found levels of 37–71% [29] and 30–
70%, respectively [5]. From these values, it can be con-
cluded that HbA2 levels in HbE/b-thal patients vary between
3% and 6%. Another report indicated that that the HbA2 level
in HbE/b-thal patients is in the range of 4–4.5% [30].Relationship between SNPs distribution and clinical
appearance
The XmnI locus in our patients included 14% minor allele,
which is within the scope of other Asian distribution studies,which reported the range of minor allele in this locus to be
8–36%. A study in Pakistan reported that a minor allele in
the XmnI locus has a frequency of 23–36% [31], whereas this
was reported to be 16% [32] and 8% [33] in Indian and Malay
populations, respectively. In accordance with the data from
the HapMap project (updated 2012), the rs11886868 geno-
type has a wide distribution that varies in populations
throughout the world. Major CC alleles are widespread in
the Asian population, including China and Japan (80–95%),
whereas the TT alleles are most widely documented in the
populations of Europe and Latin American plains [34]. The
distribution of rs11886868 genotype in this study has a sim-
ilar frequency with the populations of China and Thailand,
as reported by Pakdee and colleagues [35]. The rs766432
allele distribution in this study followed the pattern of alle-
les seen in almost all of the world’s populations. Various
populations, including whites in Europe, the population of
white Americans, and Asian populations (e.g., China, Japan,
and India), indicate that the major allele of A has a fre-
quency of 51–88%. The rs9399137 genotype had a similar
distribution in various ethnic groups. European populations
presented genotypes of CC, CT, and TT as follows: 4.5%,
31.2%, and 64.3%, respectively. The Asian population, how-
ever, shows a diverse variation: 2.4–12.8% for CC, 38–
42.9% for CT, and 48–54% for TT [34].
Quantitative trait locus either on the XmnI locus,
rs9399137, rs11886868, or rs766432 in b-thal patients
showed no significant relationship, in either the HbF level
or clinical degree. There are two possibilities to explain this
condition. Almost all allele mutations in b-thal patients
were a combination of b0 and b+ (severe). By contrast, the
HbF and clinical appearance of these patients were pooled
in the severe-type condition. In HbE/b-thal patients, there
were three SNPs, namely, XmnI, rs11886868, and
rs766432, which were significantly associated with either
HbF levels or the degree of clinical patients. Nevertheless,
the rs9399137 genotype did not show a similar relationship.
XmnI polymorphism has a coefficient determinant of
3.2% (p = .028; Table 5). This number is in the moderate
value range compared with a previous study, in which SNP
rs7482144 (XmnI locus) explained 2.2% of the variation in
HbF production for SCD cases [36]. A higher variation was
found in the study of Chinese populations (9%) [37] and in
a European study (10.2%) [38].
The rs766432 and rs11886868 loci are the SNPs in BCL11A
genes that are known to be associated with increasing HbF
levels. The gene is a kind of regulator responsible for the
transition of HbF into HbA [39,40]. Studies on populations
in Europe and Central Asia showed that rs11886868 had a
strong relationship with the increase in HbF, in both normal
individuals and thalassemia patients [12,13,41]. In a previ-
ous study, a group of researchers considered that rs766432
had a better relationship with the percentage of HbF in var-
ious cases of hemoglobinopathies in Thai, Chinese, and Afri-
can American populations [42]. The SNP rs766432 was also
subsequently found to play a role in other Thai populations
[43]. Thus, our finding is in line with previous studies con-
firming that SNP rs766432 has a better correlation with
increasing HbF levels among thalassemia patients. SNP
rs9399137, however, neither significantly correlated with
HbF concentrations nor with the degree of clinical presenta-
tions. These findings are thus not consistent with the data
62 L. Rujito et al.previously reported, such as those on European [11], Brazil-
ian, or African-American populations [13,36], which
reported the effect of variation of rs9399137 on HbF con-
centration. However, when considering other genetic epi-
demiology studies, our data are in accordance with those
identified in several research centers, including data from
studies in Hong Kong [44], Cameroon [45], and the Middle
East [46]. These different results between cross studies
demonstrate the fact that the influence of SNPs can be dif-
ferent among different regions, reflecting a link between
ethnicity and other genetic susceptibility factors.
The combination of the four alleles studied indicated
that the CAT allele is a common allele in this population.
In another section, the +CCC alleles provide a good explana-
tion of the change in HbF levels compared with the other
allele population. The combination of these alleles has a
determinant value of 10.7% against HbF changes in HbE/b-
thal patients. Similar findings were reported by Banan
et al. [47] who reported that the +CC allele for XmnI,
rs766432, and rs9399137 showed a good response to changes
in HbF in patients with thalassemia intermedia receiving
hydroxyurea supplementation. In addition, the combination
of alleles +CCC contributed to increase HbF levels (about
17.5%) among SCD patients in African populations [48].
The findings of genetic epidemiology in this study comple-
ment previous data indicating that variations of SNP loci
in the XmnI site, BCL11A, and HBS1L-MYB are specific to a
particular geographical area, although this is not a causal
relationship.
Conclusion
We have herein reported that SNPs of the XmnI site,
rs766432, and rs11886868 have a relationship with HbF
levels and the clinical appearance among HbE/b-thal
patients in an Indonesian cohort, whereas rs9399137 did
not modify either HbF or clinical presentation. This study
also reported that the SNPs had no correlation with either
the HbF level or the clinical presentation of b-thal patients.
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